Argenx up 7% as rival Biohaven drug study disappoints

argenx SE

29/05/2024 15:54

** Argenx  ARGX.BR  rise as much as 7.2% on Brussels' BEL20
 .BFX  after a disappointing study from Biohaven's  BHVN.N 
protein-degrader drug heavily hit its Wall Street-listed rival 
** One trader says the news is a "net positive" for Argenx as
some investors had seen the data as a price overhang 
** Biohaven last down 20%. Data from early-stage study of its
experimental drug BHV-1300 fell short of investor expectations  
** Argenx up 4.8% by 1450 GMT. Stock up 3% YTD

 (Reporting by Danilo Masoni; Editing by Amanda Cooper)
 ((Danilo.Masoni@TR.com))